Vaccine Immunity and Inflammation in the Aging Person Living With HIV
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorHennepin Healthcare Research Institute
About this trial
This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.
Eligibility criteria
Qualifiers
Age>=18 years
HIV Diagnosis
On Antiretroviral Therapy with HIV Viral Load<200 within last year
Disqualifiers
Other significant immunosuppressing condition
Age< 18 years
Pregnancy (at enrollment)
Contraindication to pneumococcal vaccination
Trial design
Treatments tested in this trial
- Conjugate Pneumococcal Vaccine 20 (PCV20)
Treatment groups
250 Participants
are divided into 1 treatment groupSponsors and collaborators
Hennepin Healthcare Research Institute
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov